Prevenar 13 is a vaccine, which is a type of medicine ... Prevenar 13 is a mixture of the outer sugar coating (polysaccharide) from 13 different strains or serotypes of bacteria called ...

However, as with polysaccharide vaccines in general ... To improve the immunological response, conjugate vaccines in which meningococcal polysaccharides are covalently linked to a carrier protein ...

Quadrivalent polysaccharide–protein conjugate vaccines against serogroups A, C, W and Y are currently licensed worldwide. Recommendations for use vary by country but include routine vaccination ...

Babies treated with antibiotics in the first few weeks of their life are likely to show weaker immune responses to essential ...

In addition to increasing vaccine coverage in older adults, they need to monitor the changing epidemiology of pneumococcal serotypes causing invasive disease. [134] In the face of these changes ...

Participants were randomized to receive a single dose of either one of three lots of CAPVAXIVE or PPSV23 (pneumococcal 23-valent polysaccharide ... 13-valent conjugate vaccine], or cohort 3 ...

Pneumococcal 20-valent conjugate vaccine (diphtheria CRM197 ... followed 1 month later with 23-valent polysaccharide vaccine (PPSV23). The immune responses to Prevnar 20 in patients aged 18 ...